| Product Code: ETC6186771 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Ravi Bhandari | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
Though onchocerciasis, also known as river blindness, is not endemic to Australia, the market still exists in the context of global health initiatives and pharmaceutical exports. Australia participates in research collaborations and contributes to the global supply chain of antiparasitic medications like ivermectin. The market is limited domestically but benefits from Australia involvement in international aid programs and global efforts to eliminate neglected tropical diseases. The niche nature of the market means it is primarily driven by humanitarian funding rather than domestic healthcare needs.
Although onchocerciasis, or river blindness, is not endemic in Australia, the market is influenced by global pharmaceutical development, especially through international aid and disease eradication programs. Australia biotech companies and research institutions are increasingly participating in global neglected tropical disease (NTD) initiatives, contributing to diagnostic tools and drug development. Interest in this market is also linked to Australia broader engagement in global public health efforts, creating opportunities for research and export of medical innovations.
Australia Onchocerciasis Market is limited in scope due to the non-endemic nature of the disease in the region, resulting in low market demand and limited research interest. Consequently, this leads to low investment from pharmaceutical companies and minimal government focus, stalling potential growth or advancements in diagnostic tools and medications.
Although Onchocerciasis, or river blindness, is not endemic to Australia, there is an emerging niche investment opportunity in pharmaceutical research, diagnostics, and public health initiatives targeting imported or travel-related cases. Companies can invest in R&D collaborations for global disease eradication programs, particularly through the World Health Organization or NGOs. Biotechnology firms focusing on anti-parasitic drug development and advanced molecular diagnostics can find funding and licensing opportunities through global health initiatives.
Although onchocerciasis (river blindness) is not endemic in Australia, government health agencies still maintain surveillance protocols for imported cases. Policies through the Department of Health and Therapeutic Goods Administration (TGA) provide guidance on the diagnosis and management of imported tropical diseases. Australia support for global initiatives like WHOs Neglected Tropical Diseases program also plays a role in policy formulation and research investment.
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Australia Onchocerciasis Market Overview |
3.1 Australia Country Macro Economic Indicators |
3.2 Australia Onchocerciasis Market Revenues & Volume, 2021 & 2031F |
3.3 Australia Onchocerciasis Market - Industry Life Cycle |
3.4 Australia Onchocerciasis Market - Porter's Five Forces |
3.5 Australia Onchocerciasis Market Revenues & Volume Share, By Diagnosis, 2021 & 2031F |
3.6 Australia Onchocerciasis Market Revenues & Volume Share, By Treatment, 2021 & 2031F |
3.7 Australia Onchocerciasis Market Revenues & Volume Share, By Drug, 2021 & 2031F |
3.8 Australia Onchocerciasis Market Revenues & Volume Share, By Route of Administration, 2021 & 2031F |
3.9 Australia Onchocerciasis Market Revenues & Volume Share, By End User, 2021 & 2031F |
3.10 Australia Onchocerciasis Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F |
4 Australia Onchocerciasis Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing awareness and screening initiatives for onchocerciasis in Australia |
4.2.2 Government funding and support for research and development in the field of onchocerciasis |
4.2.3 Growing prevalence of onchocerciasis cases in Australia |
4.3 Market Restraints |
4.3.1 Limited availability of effective treatment options for onchocerciasis |
4.3.2 Challenges in reaching remote and rural areas for diagnosis and treatment |
4.3.3 Lack of skilled healthcare professionals specializing in onchocerciasis management |
5 Australia Onchocerciasis Market Trends |
6 Australia Onchocerciasis Market, By Types |
6.1 Australia Onchocerciasis Market, By Diagnosis |
6.1.1 Overview and Analysis |
6.1.2 Australia Onchocerciasis Market Revenues & Volume, By Diagnosis, 2021- 2031F |
6.1.3 Australia Onchocerciasis Market Revenues & Volume, By Physical Examination, 2021- 2031F |
6.1.4 Australia Onchocerciasis Market Revenues & Volume, By Skin Biopsy, 2021- 2031F |
6.1.5 Australia Onchocerciasis Market Revenues & Volume, By Mazzotti Test, 2021- 2031F |
6.1.6 Australia Onchocerciasis Market Revenues & Volume, By Nodulectomy, 2021- 2031F |
6.1.7 Australia Onchocerciasis Market Revenues & Volume, By PCR Test, 2021- 2031F |
6.1.8 Australia Onchocerciasis Market Revenues & Volume, By Others, 2021- 2031F |
6.2 Australia Onchocerciasis Market, By Treatment |
6.2.1 Overview and Analysis |
6.2.2 Australia Onchocerciasis Market Revenues & Volume, By Medication, 2021- 2031F |
6.2.3 Australia Onchocerciasis Market Revenues & Volume, By Supportive Care, 2021- 2031F |
6.2.4 Australia Onchocerciasis Market Revenues & Volume, By Others, 2021- 2031F |
6.3 Australia Onchocerciasis Market, By Drug |
6.3.1 Overview and Analysis |
6.3.2 Australia Onchocerciasis Market Revenues & Volume, By Ivermectin, 2021- 2031F |
6.3.3 Australia Onchocerciasis Market Revenues & Volume, By Moxidectin, 2021- 2031F |
6.3.4 Australia Onchocerciasis Market Revenues & Volume, By Others, 2021- 2031F |
6.4 Australia Onchocerciasis Market, By Route of Administration |
6.4.1 Overview and Analysis |
6.4.2 Australia Onchocerciasis Market Revenues & Volume, By Oral, 2021- 2031F |
6.4.3 Australia Onchocerciasis Market Revenues & Volume, By Others, 2021- 2031F |
6.5 Australia Onchocerciasis Market, By End User |
6.5.1 Overview and Analysis |
6.5.2 Australia Onchocerciasis Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.5.3 Australia Onchocerciasis Market Revenues & Volume, By Homecare, 2021- 2031F |
6.5.4 Australia Onchocerciasis Market Revenues & Volume, By Specialty Clinics, 2021- 2031F |
6.5.5 Australia Onchocerciasis Market Revenues & Volume, By Others, 2021- 2031F |
6.6 Australia Onchocerciasis Market, By Distribution Channel |
6.6.1 Overview and Analysis |
6.6.2 Australia Onchocerciasis Market Revenues & Volume, By Hospital Pharmacy, 2021- 2031F |
6.6.3 Australia Onchocerciasis Market Revenues & Volume, By Online Pharmacy, 2021- 2031F |
6.6.4 Australia Onchocerciasis Market Revenues & Volume, By Retail Pharmacy, 2021- 2031F |
7 Australia Onchocerciasis Market Import-Export Trade Statistics |
7.1 Australia Onchocerciasis Market Export to Major Countries |
7.2 Australia Onchocerciasis Market Imports from Major Countries |
8 Australia Onchocerciasis Market Key Performance Indicators |
8.1 Number of onchocerciasis screening programs implemented |
8.2 Percentage increase in government funding allocated for onchocerciasis research |
8.3 Rate of adoption of new onchocerciasis treatment protocols |
8.4 Patient adherence to onchocerciasis treatment regimens |
8.5 Number of healthcare professionals trained in onchocerciasis management |
9 Australia Onchocerciasis Market - Opportunity Assessment |
9.1 Australia Onchocerciasis Market Opportunity Assessment, By Diagnosis, 2021 & 2031F |
9.2 Australia Onchocerciasis Market Opportunity Assessment, By Treatment, 2021 & 2031F |
9.3 Australia Onchocerciasis Market Opportunity Assessment, By Drug, 2021 & 2031F |
9.4 Australia Onchocerciasis Market Opportunity Assessment, By Route of Administration, 2021 & 2031F |
9.5 Australia Onchocerciasis Market Opportunity Assessment, By End User, 2021 & 2031F |
9.6 Australia Onchocerciasis Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
10 Australia Onchocerciasis Market - Competitive Landscape |
10.1 Australia Onchocerciasis Market Revenue Share, By Companies, 2024 |
10.2 Australia Onchocerciasis Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here